Descriptors
Classification > W - MEDICINE > WP - GYNECOLOGY > WP 870 - Breast - - Neoplasms
WP 870 - Breast - - Neoplasms |
Documents disponibles dans cette catégorie (55)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
Informed choice on breast cancer screening / Laurence Kohn / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
Informed choice on breast cancer screening : Messages to support informed decision - Synthesis [printed text] / Laurence Kohn , Author ; Françoise Mambourg , Author ; Jo Robays, Author ; Michel Albertijn, Author ; Sabine Janssens, Author ; Kathleen Hoefnagels, Author ; Magali Ronsmans, Author ; Pascale Jonckheer , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 4 p. : ill. ; A4. - (KCE Reports. Good Clinical Practice (GCP); 216CS) .
ISSN : D/2014/10.273/03 : € 0,00
Study 2010-03
Languages : English (eng)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
2010-03 ; Breast Neoplasms ; Decision Making ; Decision Support Techniques ; Health Communication ; Mass Screening ; R216Link for e-copy: https://doi.org/10.57598/R216CS Format of e-copy: PDF (146 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3334 Copies(0)
Status No copy Kwaliteitsindicatoren in oncologie / Sabine Stordeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Kwaliteitsindicatoren in oncologie : borstkanker [printed text] / Sabine Stordeur, Author ; France Vrijens , Author ; Joan Vlayen , Author ; Koen Beirens, Author ; Stephan Devriese , Author ; E. Van Eycken, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - IX, 206 p. : ill. ; A4. - (KCE Reports A. Good Clinical Practice (GCP); 150A) .
ISSN : D/2010/10.273/99 : € 0,00
studie nr : 2008-52
Languages : English (eng) Dutch (nla)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
2008-52 ; Breast Neoplasms ; Physician's Practice Patterns ; Quality Assurance, Health Care ; Quality Indicators, Health Care ; Quality of Health Care ; R150Abstract: Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) ontwikkelde een lijst van indicatoren om de zorgkwaliteit van borst- en teelbalkanker te meten. Hoewel er nog nood is aan meer diepgaande analyses, kan toch al worden vastgesteld dat de zorgkwaliteit bij deze kankers verbetert. Zo is de overleving op 5 jaar licht gestegen. Toch is er nog ruimte voor verbetering op gebied van diagnose, behandeling en opvolging. De zorg is ook nog teveel versnipperd. Het KCE pleit voor centralisatie in ziekenhuizen met voldoende ervaring met de behandeling van de aandoening. Contents note: ABBREVIATIONS 4 -- 1 INTRODUCTION 5 -- 2 SELECTION PROCESS OF QUALITY INDICATORS 6 -- 2.1 METHODOLOGY 6 -- 2.1.1 Literature search 6 -- 2.1.2 Addition of guideline-based quality indicators 6 -- 2.1.3 Selection process 6 -- 2.2 RESULTS 7 -- 3 DATA SELECTION 10 -- 3.1 PRIMARY SELECTION 10 -- 3.2 ADDITIONAL SELECTION 12 -- 3.3 EXPLORATION AND CHECK OF BCR DATA 13 -- 3.4 DATA LINKAGE 16 -- 3.4.1 Linking BCR data to IMA data 16 -- 3.4.2 Linking BCR data to MCD data 16 -- 4 DESCRIPTIVE STATISTICS 18 -- 4.1 DEMOGRAPHIC INFORMATION 18 -- 4.2 TUMOUR CHARACTERISTICS 18 -- 4.2.1 Solitary vs. multiple tumours 18 -- 4.2.2 Morphology 19 -- 4.2.3 TNM staging 19 -- 4.2.4 Incidence rates 21 -- 4.3 DIAGNOSIS AND STAGING 22 -- 4.4 TREATMENT 23 -- 4.5 HOSPITALIZATION 26 -- 5 INDICATOR RESULTS 27 -- 5.1 OVERALL MEASURABILITY OF THE SELECTED QUALITY INDICATORS 27 -- 5.2 INDICATOR RESULTS 34 -- 5.2.1 Survival 34 -- 5.2.2 Diagnosis and staging 37 -- 5.2.3 Neoadjuvant treatment 42 -- 5.2.4 Surgery 43 -- 5.2.5 Adjuvant treatment 43 -- 5.2.6 Treatment of metastatic cancer 46 -- 5.2.7 Follow-up 47 -- 5.2.8 Histopathologic examination 48 -- 5.3 RELATIONSHIP BETWEEN HOSPITAL VOLUME, PROCESSES AND OUTCOMES 48 -- 6 DISCUSSION 52 -- 6.1 INDICATOR RESULTS 52 -- 6.1.1 National level 52 -- 6.1.2 Variability of practices between centres 57 -- 6.1.3 Volume outcome relationship 58 -- 6.2 INDICATORS MEASURABILITY AND INTERPRETABILITY 59 -- 6.3 USE OF INDICATORS FOR QUALITY IMPROVEMENT 62 -- 6.4 CONCLUSIONS 63 -- 7 APPENDIX 64 -- 7.1 SEARCH STRATEGY OVID MEDLINE 64 -- 7.2 OVERVIEW OF ALL IDENTIFIED QUALITY INDICATORS 65 -- 7.3 EVALUATION SCORES OF THE LONG LIST OF QUALITY INDICATORS 90 -- 7.4 METHODS: CONSTRUCTION OF AN ALGORITHM TO ATTRIBUTE A PATIENT TO A -- HOSPITAL 99 -- 7.4.1 Introduction 99 -- 7.4.2 Methods 99 -- 7.4.3 Results 102 -- 7.5 METHODS OF ANALYSIS 106 -- 7.5.1 Descriptive statistics by type of outcome 106 -- 7.5.2 Graphical description of the variability per centre (funnel plots) 107 -- 7.5.3 Volume outcome analyses 107 -- 7.6 QUALITY INDICATORS: GENERAL INDICATORS 108 -- 7.6.1 BC1: overall 5-year survival rate by stage 108 -- 7.6.2 BC2: disease specific 5 year survival by stage 112 -- 7.6.3 BC3: disease-free 5-year survival rate by stage 113 -- 7.6.4 BC4: 5-year local recurrence rate after curative surgery, by stage 115 -- 7.6.5 BC5: Proportion of breast cancer women discussed at the multidisciplinary team -- meeting 117 -- 7.6.6 BC6: Proportion of women with breast cancer who participate in clinical trials 120 -- 7.7 QUALITY INDICATORS: DIAGNOSIS AND STAGING 121 -- 7.7.1 BC7: Proportion of women with class 3, 4 or 5 abnormal mammograms having an -- assessment with a specialist within 2 months of mammography 121 -- 7.7.2 BC8: Proportion of women with class 3, 4 or 5 abnormal mammograms who have at -- least one of the following procedures within 2 months after communication of the screening -- result: mammography, ultrasound, fine-needle aspiration, or percutaneous biopsy 122 -- 7.7.3 BC9: Proportion of newly diagnosed cStage I-III breast cancer women who underwent -- two-view mammography or breast sonography within 3 months prior to surgery 123 -- 7.7.4 BC10: Proportion of women who received axillary ultrasonography with fine needle -- aspiration cytology of the axillary lymph nodes before any treatment 127 -- 7.7.5 BC11: Proportion of women in whom human epidermal growth factor receptor 2 -- (HER2) status was assessed before any systemic treatment 129 -- 7.7.6 BC12: Proportion of women in whom a ER and PgR status assessment were performed -- before any systemic treatment 131 -- 7.7.7 BC13: Proportion of breast cancer women with cytological and/or histological -- assessment before surgery 134 -- 7.7.8 BC14: Proportion of sentinel lymph nodes biopsy in cN0 women without -- contraindications 136 -- 7.8 QUALITY INDICATORS: NEO-ADJUVANT TREATMENT 138 -- 7.8.1 BC15: Proportion of operable cT2-T3 women who received neoadjuvant systemic -- therapy 138 -- 7.9 QUALITY INDICATORS: SURGERY. 141 -- 7.9.1 BC16: Proportion of breast cancer women who underwent an ALND after positive -- SNLB > 2 mm 141 -- 7.9.2 BC17: Proportion of women with high-grade and/or palpable and/or large DCIS of the -- breast who had negative margins after surgery, whatever the surgical option (local wide -- excision or mastectomy) 143 -- 7.9.3 BC18: Proportion of cStage I and II women who undergo breast-conserving surgery / -- mastectomy 144 -- 7.9.4 BC19: Proportion of women with breast cancer recurrence after breast conserving -- surgery who are treated by a mastectomy 147 -- 7.10 QUALITY INDICATORS: ADJUVANT TREATMENT 149 -- 7.10.1 BC20: Proportion of women with a breast cancer who are receiving intravenous -- chemotherapy for whom the planned chemotherapy regimen (which includes, at a minimum: -- drug[s] prescribed, dose, and duration) is documented prior to the initiation, and at each -- administration of the treatment regimen 149 -- 7.10.2 BC21: Proportion of women receiving adjuvant systemic therapy after breast surgery -- for invasive breast cancer 151 -- 7.10.3 BC22: Proportion of women with hormone receptor positive invasive breast cancer or -- DCIS who received adjuvant endocrine treatment (Tamoxifen/AI) 155 -- 7.10.4 BC23: Proportion of women with HER2 positive, node positive or high-risk node -- negative breast cancer (tumour size > 1 cm), having a left ventricular ejection fraction of 55% -- who received chemotherapy and Trastuzumab 157 -- 7.10.5 BC24: Proportion of women treated by Trastuzumab in whom cardiac function is -- monitored every 3 months 158 -- 7.10.6 BC25: Proportion of women who received radiotherapy after breast conserving surgery -- 160 -- 7.10.7 BC26: Proportion of women who underwent a mastectomy and having 4 positive -- nodes who received radiotherapy on axilla following ALND 163 -- 7.11 QUALITY INDICATORS: TREATMENT OF METASTATIC CANCER 165 -- 7.11.1 BC27: Proportion of women with HER2 positive metastatic breast cancer who received -- Trastuzumab with/without non-anthracycline based chemotherapy or endocrine therapy as -- first-line treatment 165 -- 7.11.2 BC28: Proportion of metastatic breast cancer women who receive systemic therapy as -- 1st and/or 2nd line treatment 166 -- 7.11.3 BC29: Proportion of women with metastatic breast cancer and lytic bone metastases -- who received biphosphonates 169 -- 7.12 QUALITY INDICATORS: FOLLOW-UP 171 -- 7.12.1 BC30: Proportion of women who benefit from an annual mammography after a history -- of breast cancer 171 -- 7.13 QUALITY INDICATORS: HISTOPATHOLOGICAL EXAMINATION 174 -- 7.13.1 BC31: Proportion of breast cancer resection pathology reports that include the tumour -- size (macro-and microscopically invasive and DCIS), the histologic type of the primary tumour, -- the pT category (primary tumour), the pN category (regional lymph nodes including numbers), -- the LVI and the histologic grade 174 -- 7.13.2 BC32: Proportion of women with invasive breast cancer undergoing ALND and having -- 10 or more lymph nodes removed 175 -- 7.14 ADMINISTRATIVE CODES 177 -- 7.14.1 General indicators 177 -- 7.14.2 Diagnosis and staging 177 -- 7.14.3 Surgery 182 -- 7.14.4 (Neo)adjuvant treatment 186 -- 7.14.5 Follow-up 201 -- 8 REFERENCES 202 Link for e-copy: https://doi.org/10.57598/R150A Format of e-copy: PDF (3,1 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2323 Copies(0)
Status No copy Mammacarcinoom / Integraal kankercentrum Nederland (2012)
Mammacarcinoom : Richtlijn 2012 [printed text] . - Integraal kankercentrum Nederland, 2012 . - 282 p. : ill., ; 23 cm.
€ 0,00
Languages : Dutch (dut)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
Breast Neoplasms ; Mammography ; therapeutic use ; Ultrasonography, MammaryRecord link: https://kce.docressources.info/index.php?lvl=notice_display&id=4270 Hold
Place a hold on this item
Copies(1)
Barcode Call number Media type Location Section Status 10273-03308 WP 870 / MAM Book KCE Library (10.124) Available MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2018)
MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer [printed text] / Lorena San Miguel , Author ; Cécile Dubois , Author ; Sophie Gerkens , Author ; Jillian Harrison, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2018 . - 70 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 298) .
€ 0,00
Languages : English (eng)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
2017-01 ; Breast Neoplasms ; Gene Expression Profiling ; R298Contents note: SCIENTIFIC REPORT 6 -- 1 INTRODUCTION AND SCOPE 6 -- 2 BREAST CANCER 7 -- 2.1 EPIDEMIOLOGY 7 -- 2.2 PROGNOSIS AND TREATMENT 7 -- 3 MAMMAPRINT® IN EARLY BREAST CANCER 8 -- 3.1 MAMMAPRINT® 8 -- 3.2 METHODS FOR ASSESSMENT OF CLINICAL UTILITY 8 -- 3.3 RESULTS ON THE CLINICAL UTILITY OF MAMMAPRINT® 8 -- 4 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC STUDIES 12 -- 4.1 INTRODUCTION 12 -- 4.2 METHODS 12 -- 4.2.1 Search strategy 12 -- 4.2.2 Selection procedure 12 -- 4.2.3 Selection criteria 12 -- 4.3 OVERVIEW OF ECONOMIC EVALUATIONS 13 -- 4.3.1 Type of economic evaluation 14 -- 4.3.2 Time frame of analyses and discounting 14 -- 4.3.3 Perspective 15 -- 4.3.4 Population 15 -- 4.3.5 Comparators 15 -- 4.3.6 Cost and outcome inputs 15 -- 4.3.7 Modelling 16 -- 4.3.8 Results 17 -- 4.3.9 Sensitivity analysis 22 -- 4.3.10 Conflict of interest 22 -- 4.4 DISCUSSION AND CONCLUSIONS 22 -- 5.2 PATIENTS’ SELECTION 25 -- 5.4.2 Characteristics of the subset of patients for the Belgian context 30 -- 5.4.3 Target population and projection 32 -- 6 CHEMOTHERAPY USE AND RELATED COSTS IN EARLY BREAST CANCER PATIENTS IN BELGIUM 36 -- 6.1 CHEMOTHERAPY COMBINATIONS 36 -- 6.2 OTHER NON-PHARMACOLOGICAL CHEMOTHERAPY-RELATED COSTS 37 -- 6.2.1 Chemotherapy administration 37 -- 6.2.2 Blood tests 37 -- 6.2.3 Costs of prophylaxis or management of common chemotherapy related adverse events (AEs) 38 -- 6.2.4 Other costs 39 -- 6.2.5 Limitations 40 -- 7.1 CLINICAL UTILITY OF MAMMAPRINT® 43 -- 7.1.1 The evidence 43 -- 7.2 GENERALIZABILITY OF ECONOMIC EVALUATIONS TO THE BELGIAN CONTEXT 46 -- APPENDICES 48 -- REFERENCES 67 Link for e-copy: https://doi.org/10.57598/R298C Format of e-copy: PDF (854 KB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4355 De moleculaire profileringstesten en hun bijdrage aan de beslissing tot behandeling met adjuvante chemotherapie bij borstkanker / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
De moleculaire profileringstesten en hun bijdrage aan de beslissing tot behandeling met adjuvante chemotherapie bij borstkanker : – een Rapid Assessment – Synthese [printed text] / Lorena San Miguel , Author ; Joan Vlayen , Author ; Chris De Laet , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2015 . - 13 p. : ill., ; A4. - (KCE Reports A. Health Technology Assessment (HTA); 237As) .
ISSN : D/2015/10.273/10 : € 0,00
Studie 2014 2014-15_HTA_Gene_expr_profiling
Languages : Dutch (nla)
Descriptors: Classification
WP 870 - Breast - - Neoplasms
Indexation
2014-15 ; Breast Neoplasms ; Gene Expression Profiling ; Immunohistochemistry ; R237Abstract: Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) voerde een studie uit over het moleculair testen van de borstkankercellen zelf. Op basis van deze testen kan men de moleculaire eigenschappen opsporen die typisch zijn voorde kanker, een prognose stellen en kan een bijna « gepersonaliseerde » behandelstrategie worden bepaald. Contents note: DOEL VAN DIT RAPPORT 3 -- KERNBOODSCHAPPEN 3 -- CONTEXT 4 -- DOEL VAN DEZE STUDIE . 5 -- 1. WAT IS DE KLINISCHE VALIDITEIT EN HET KLINISCH NUT VAN GEP-TESTEN EN EXPANDED IHC-TESTEN VOOR BORSTKANKER IN EEN VROEG STADIUM, VERGELEKEN MET DE CONVENTIONELE METHODEN VAN RISICOSTRATIFICATIE BIJ DEZE TUMOREN? 8 -- 2. WAT IS DE KOSTENEFFECTIVITEIT VAN GEP-TESTEN EN EXPANDED IHC-TESTEN VOOR BORSTKANKER IN EEN VROEG STADIUM, VERGELEKEN MET DE CONVENTIONELE METHODEN VAN RISICOSTRATIFICATIE BIJ DEZE TUMOREN? 9 -- 3. WAT ZOU DE BUDGETTAIRE IMPACT ZIJN VAN DE INVOERING VAN DEZE TESTEN, VERGELEKEN MET DIE VAN DE CONVENTIONELE METHODEN VAN RISICOSTRATIFICATIE DIE MOMENTEEL IN BELGIË WORDEN GEBRUIKT? 10 -- BELEIDSAANBEVELINGEN 12 Link for e-copy: https://doi.org/10.57598/R237AS Format of e-copy: PDF (313 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3496 Copies(0)
Status No copy Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome / Jo Robays / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
PermalinkOncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome / Jo Robays / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
PermalinkOncogenetische testen en follow-up van vrouwen met erfelijke borst- of ovariumkanker, Li-Fraumeni-syndroom en Cowden-syndroom / Jo Robays / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
PermalinkOpportunité de dépistage du cancer du sein chez les femmmes de 40 à 49 ans / Marina Puddu / Bruxelles [Belgium] : Institut Scientifique de la Santé Publique (2005)
PermalinkOpsporing van borstkanker tussen 40 en 49 jaar / Françoise Mambourg / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkOpsporing van borstkanker tussen 70 en 74 jaar / Françoise Mambourg / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
PermalinkOpsporing van borstkanker tussen 70 en 74 jaar / Françoise Mambourg / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
PermalinkLe programme de dépistage du cancer du sein / Douchan Beghin / Bruxelles : Ministère de la Communauté Française - Direction générale de la santé (2004)
PermalinkQuality indicators in oncology / Sabine Stordeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkQuel rôle pour le test Mammaprint® dans les décisions de chimiothérapie adjuvante en cas de cancer du sein au stade précoce ? / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2018)
Permalink